Teva Parenteral Medicines, Inc. v. Eighth Judicial District Court
Annotate this Case
The Supreme Court granted in part and denied in part a petition for a writ of mandamus stemming from lawsuits brought against generic drug manufacturers for selling vials of propofol to ambulatory surgical centers despite an allegedly foreseeable risk that they would be used on multiple patients, holding that some of the claims were preempted.
Plaintiffs alleged that Petitioners knew or should have known that selling 50 mL vials of propofol, as opposed to 20 mL vials, to ambulatory surgical centers with high patient turnover was unsafe due to the risk of contamination from multi-dosing. Petitioners filed a motion to dismiss, alleging that Plaintiff's claims conflicted with federal law. The district courts summarily denied the motions to dismiss. Petitioners then filed the instant writ petition. The Supreme Court granted the writ in part, holding (1) Plaintiffs' negligence cause of action and request for punitive damages survived; but (2) the remainder of Plaintiffs' causes of action were preempted.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.